8-K: Immuneering Reports Positive Phase 2a Data and Outlines 2025 Plans, Bolstering Cash Runway into 2026

Immuneering Corporation announced positive data from its Phase 2a trial of IMM-1-104, a clinical trial supply agreement with Regeneron, the appointment of a new Chief Medical Officer, and an extended cash runway into 2026.

Summary

• Immuneering Corporation reported its fourth quarter and full year 2024 financial results and provided business updates.
• The company highlighted positive data from its ongoing Phase 2a trial of IMM-1-104, showing encouraging responses in combination with chemotherapy in first-line pancreatic cancer.
• An observed ORR of 43% and DCR of 86% were reported for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP).
• An observed ORR of 50% was reported for IMM-1-104 in combination with modified FOLFIRINOX (mFFX), compared to historic benchmarks of 23% and 32% ORR for either chemotherapy agent alone.
• Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo (cemiplimab) in non-small cell lung cancer.
• The company expects additional IMM-1-104 Phase 2a data updates and the initiation of new IMM-1-104 combination arms in 2025.
• Planning is underway for a potential IMM-1-104 global pivotal trial.
• Dr. Igor Matushansky was appointed as Chief Medical Officer.
• The company's cash runway has been extended into 2026.
• Cash, cash equivalents, and marketable securities as of December 31, 2024, were $36.1 million, compared to $85.7 million as of December 31, 2023.
• Net proceeds of $13.7 million were raised from the company's ATM facility in January 2025.
• The company expects multiple data events in 2025, starting with an update from the IMM-1-104 Phase 2a trial in the second quarter.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to promising clinical data, a strategic collaboration, and an extended cash runway. However, the decreased cash position and net losses temper the overall sentiment.

Positives

• Positive Phase 2a data for IMM-1-104 in combination with chemotherapy in pancreatic cancer shows promising response rates.
• The clinical trial supply agreement with Regeneron expands the potential applications of IMM-1-104.
• The appointment of Dr. Igor Matushansky as Chief Medical Officer strengthens the company's clinical leadership.
• The extended cash runway into 2026 provides financial stability for ongoing and planned clinical trials.
• FDA Fast Track and Orphan Drug designations offer potential benefits for IMM-1-104 development.
• The company is planning for a potential IMM-1-104 global pivotal trial in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.

Negatives

• The company's cash position decreased from $85.7 million at the end of 2023 to $36.1 million at the end of 2024.
• The company reported a net loss attributable to common stockholders of $61.0 million, or $2.04 per share, for full year 2024, compared to $53.5 million, or $1.88 per share, for full year 2023.

Risks

• The company is subject to the risks inherent in oncology drug research and development.
• The company has incurred significant losses and may never become profitable.
• The company's approach to therapeutic intervention is unproven.
• The company relies on third parties and collaborators to conduct clinical trials and manufacture product candidates.
• The company faces the risk of potential lawsuits for infringement of third-party intellectual property.

Future Outlook

Based on current cash and operating plans, the company expects its cash runway to be sufficient to fund operations into 2026 and anticipates multiple data events in 2025, starting with an update from the IMM-1-104 Phase 2a trial in the second quarter.

Management Comments

• Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering, stated that the company was delighted to report updates from its ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients.
• Zeskind also mentioned that based on these promising results, the company has begun planning for a potential IMM-1-104 global pivotal trial in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
• Zeskind concluded that the company expects multiple data events, beginning with an update from its IMM-1-104 Phase 2a trial in the second quarter of 2025.

Industry Context

Immuneering is focusing on developing therapies for RAS-driven tumors, particularly pancreatic cancer, which aligns with the industry's growing interest in targeting these difficult-to-treat cancers. The collaboration with Regeneron to evaluate IMM-1-104 in combination with Libtayo reflects the trend of combining MEK inhibitors with checkpoint inhibitors to improve efficacy in non-small cell lung cancer.

Comparison to Industry Standards

• The reported ORR of 43% and DCR of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) and an ORR of 50% for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients are promising when compared to historic benchmarks of 23% ORR and 32% ORR for either chemotherapy agent alone.
• Companies like Novartis (MEK inhibitor Mekinist) and Array BioPharma (MEK inhibitor Braftovi) have existing MEK inhibitors on the market, but Immuneering aims to offer an improved profile with IMM-1-104.
• The $2.4 billion annual global opportunity in the aggregate for MEK inhibitors indicates a significant market potential if IMM-1-104 can demonstrate superior efficacy and tolerability.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the promising clinical data and extended cash runway.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with pancreatic cancer and other RAS-driven tumors may benefit from the development of IMM-1-104.
• The collaboration with Regeneron could lead to new treatment options for patients with non-small cell lung cancer.

Next Steps

• The company plans to release further IMM-1-104 Phase 2a data in the second quarter of 2025.
• The company intends to initiate Phase 2a arms of IMM-1-104 in combination with Libtayo in NSCLC, a G12C inhibitor in NSCLC, a PD-1 inhibitor in melanoma, and a BRAF inhibitor in melanoma in 2025.
• The company is planning for a potential IMM-1-104 global pivotal trial in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.

Key Dates

Keywords

IMM-1-104, pancreatic cancer, non-small cell lung cancer, clinical trial, Phase 2a, Regeneron, Libtayo, oncology, MEK inhibitor, FDA, Fast Track designation, Orphan Drug designation, financial results, cash runway, Immuneering